Michelson Prizes 2021
The Michelson Prizes are annual awards of $150,000, which support young investigators under the age of 35 who are using disruptive concepts and inventive processes to significantly advance human immunology and vaccine and immunotherapy discovery research for major global diseases. The Prizes are funded by the Michelson Medical Research Foundation and overseen by the Human Vaccines Project -- the application window for the 2021 Prizes will run from April 1 – June 18, 2021.
The 2021 Michelson Prizes will be looking for research proposals in two areas:
• Human Immunology and Vaccine Research: The committee will be looking for research aimed at tackling the current roadblocks that exist in human vaccine development and expanding our limited understanding of key immune processes that are fundamental to successful vaccine and immunotherapy development.
• Climate Change and Human Immunology: The committee is looking for research that expands our understanding of the potential effects of climate change on immune function with a particular interest in research that will directly translate into vaccine and immunotherapy development to mitigate its impact.
The selection committee will be looking to support research that is both highly innovative and has the potential for high impact. Specifically, projects should propose innovative ideas and approaches that can be applied across many disease areas and states. Projects should have the potential to significantly expand our understanding of the human immune system and accelerate the development of vaccines and immunotherapies.
While the Michelson Prizes are focused on research in the fields of immunology, vaccine and immunotherapy discovery, applicants from the full spectrum of related disciplines, including clinical research, biochemistry, molecular biology, protein engineering, computer science, artificial intelligence/machine learning, biophysics, environmental health, nanotechnology, etc., are encouraged to apply.
Additional info can be found at https://www.humanvaccinesproject.org/michelsonprizes/
Articles
Virtual Workshop: Recognition And Control Of Mtb Infected Cells: From Basics To The Clinic | 13 – 14June 2023
The Stop
TB Partnership Working Group on New TB Vaccines (WGNV) and the National
Institute for Allergy and Infectious Diseases (NIAID)are
co-hosting a workshop on the topic of Recognition and Control of Mtb
Infected Cells: From Basics to the Clinic. This workshop is intended to address
the need for correlates and to identify platforms that measure recognition or
control of the infected cell - especially in humans - as identified in the EDCTP/AIGHD Global Roadmap for
Research and Development of New TB Vaccines and the Strategic Framework for
New TB Vaccines in the Stop TB Partnership Global Plan to End TB 2023 - 2030.
The overall goals of this workshop
are to:
- elucidate the mechanisms by
which the immune system recognizes the Mtb-infected cell
- explore the degree to which
such recognition can lead to control of the intracellular microbe, and
- discuss the translational
implications of these observations
The workshop format will be largely
discussion-based. Each session will have three short presentations that will
provide a high-level overview of key topics within the session theme, followed
by a discussion between the session chairs, speakers, and participants.
Click here
to view the programme and
speakers.
This workshop is free of charge and
open to any participants interested in this topic.
Ssi/Isid Infectious Diseases Research Fellowships | Deadline For Applications: 16 June 2023
The International Society for Infectious Diseases (ISID) and the Swiss
Society for Infectious Diseases (SSI) are inviting applications for their joint
Infectious Diseases Research Fellowship Program. The purpose of this programme
is to support infectious disease physicians and scientists from under-resourced
countries through multidisciplinary clinical and laboratory training at a
select biomedical institution in Zurich, Switzerland. The one-year SSI/ISID
Fellowship programme is open to applicants who are 40 years or younger,
citizens and permanent residents of under-resourced countries or Eastern
Europe. The deadline for applications is 16 June 2023.
More information: https://na.eventscloud.com/eSites/748378/Homepage
Ethical Review Of Decentralized Clinical Trials (Dcts): Tools, Resources & Best Practices.
The MRCT Center and Medable convened a multi-stakeholder task force to address ethical and regulatory opportunities and challenges related to Decentralized Clinical Trials (DCTs). Join them on June 20, from 10 - 11 AM ET, for a joint webinar entitled, "Ethical Review of Decentralized Clinical Trials (DCTs): Tools, Resources & Best Practices."
During the webinar, Barbara Bierer (MRCT Center), Pam Tenaerts
(Medable) and Leanne Madre (Medable) will present a framework, recommendations,
and tools organized around 3 DCT domains: People, Remote Data Collection, and
Data Oversight. Best practices for the ethical review, approval, and conduct of
DCTs will be provided.
Clinical trial stakeholders (IRB/ECs,
HRPP, sites, sponsors, investigators, and others) to register for the webinar here